

Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma

GIANLUCA BRUSA¹, ELISA ZUFFA¹, CLAUDIA MARIA HATtingER², MASSIMO SERRA², DANIEL REMONDINI^{2,6}, GASTONE CASTELLANI³, SIMONA RIGHI⁴, CRISTINA CAMPIDELLI⁴, STEFANO PILERI⁴, PIER LUIGI ZINZANI⁵, ANNALISA GABRIELE⁵, MANUELA MANCINI⁵, PATRIZIA CORRADO⁵, ENZA BARBIERI¹ and MARIA ALESSANDRA SANTUCCI⁵

¹Istituto di Radioterapia 'Luigi Galvani', Università di Bologna, Via Massarenti 9, 40138 Bologna;

²Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via di Barbiano 1/10, 40136 Bologna;

³Dipartimento di Morfofisiologia Veterinaria e Produzione Animale, Università di Bologna, Ozzano Emilia, 40064 Bologna; ⁴Unità di Emolinfopatia e ⁵Laboratorio di Biologia Molecolare e Cellulare, Istituto di Ematologia e Oncologia Medica 'Lorenzo e Ariosto Seràgnoli', Università di Bologna, Via Massarenti 9, 40138 Bologna;

⁶Dipartimento di Fisica, Università di Bologna, Viale Berti-Pichat 6/2, 40136 Bologna, Italy

Received June 26, 2007; Accepted August 8, 2007

Abstract. Secondary tumors and leukemias are major complications in Hodgkin lymphoma (HL). They likely arise from clonal selection of cells that have accumulated genomic lesions induced by chemo- and radiotherapy and may be further promoted by the loss of DNA repair and/or other pathways ensuring the fidelity of replicated DNA. To distinguish genomic imbalances associated with the development of acute myeloid leukemia (AML) in HL we used an array-based comparative genomic hybridization (aCGH) strategy on whole lymph node biopsies of HL patient. Genomic imbalances (amplifications and deletions) associated with AML outcome in 3 classic HL patients, at clinical diagnosis they exhibited a discrete individual variability. Three amplifications and 5 deletions were shared by all 3 patients. They involved AFM137XA11, a 9p11.2 pericentric region; FGFR1, the FGF receptor most frequently translocated in AML; PPARBP, a co-activator of nuclear receptors RAR α , RXR and TR β 1; AFM217YD10, a 17q25 telomeric region; FGR, an SRC2 kinase involved in cytokine production by NK and CD4⁺ NKT cells; GATA3, a Th2-specific transcription factor; TOP1, involved in DNA recombination and repair; WT1, a transcription factor involved in CD8⁺ T cell response against leukaemic blasts. Immunohistochemistry confirmed aCGH results and distinguished the distribution of either amplified or deleted

gene products in neoplastic Reed-Sternberg (RS) cells and non-neoplastic lymph node components.

Introduction

Secondary malignancies are major treatment-related complications in HL and a leading cause of death of long-term survivors. They may arise from clonal selection of cells that have accumulated transforming genomic lesions induced by chemo- and radiotherapy. DNA repair defects are assumed to increase the susceptibility to treatment-related cancers (1).

Hodgkin and Reed-Sternberg (H/RS) cells, the pathognomonic cells of HL, are aberrant post-germinal center B cells that have lost their identity as a consequence of the abolition of B cell gene transcription program and evade apoptotic cell death through CD30 signaling, NF- κ B activation and Fas pathway failure (2). Virtually all H/RS cells exhibit neither clonal nor disease-specific chromosomal abnormalities that may originate from their own or their progenitor inherent genomic instability (3). The hypothesis of an unstable genetic background concurrently promoting the evasion of H/RS cell progenitors from FAS-mediated negative selection in the germinal center, accumulation of multiple genetic aberrations driving their progression towards a fully transformed phenotype and deregulated differentiation culminating in endomitosis is advanced by the findings that chromosomal abnormalities (eventually resulting in oncosuppressor loss) are not restricted to the malignant cellular context (4-8). The association of polymorphisms in DNA repair and oxidative stress response genes with an increased risk for non-Hodgkin lymphoma supports a role of individual genetic susceptibility in primary B lymphomagenesis (9,10). However, the determining factors of chromosomal lesions in HL are still elusive. Most likely, they do not include defects of nucleotide mismatch repair resulting in microsatellite instability, a putative source of genomic instability in H/RS cells (11).

Correspondence to: Dr Gianluca Brusa, Istituto di Ematologia e Oncologia Medica 'Lorenzo e Ariosto Seràgnoli', Università di Bologna - Medical School, Via Massarenti 9, 40138 Bologna, Italy
E-mail: gbrusa@alma.unibo.it

Key words: array-based comparative genomic hybridization, genomic instability, Hodgkin lymphoma, secondary acute leukemias

Genomic instability in therapy-related myelodysplastic syndromes and AMLs seems genetically determined. It might stem from defects of detoxification systems designed to limit oxidative DNA damage (driven by polymorphisms of genes involved in drug metabolism) and/or chromatin assembly factors, resulting in accumulation of double strand breaks (DSB) and high levels of sister chromatid exchange (SCE) (12,13). More recently, combined polymorphisms in human homeobox HLX1 (a determinant of hematopoietic stem cell frequency) and DNA repair RAD1 genes have been associated with an increased risk of therapy-related AML (14).

We used an aCGH strategy to detect and map genomic imbalances (amplifications and deletions) in whole formalin-fixed, paraffin-embedded lymph nodes of 3 patients with classic HL at diagnosis who developed secondary AML during the follow-up. Our results underscored 3 amplifications and 5 deletions common to all 3 patients. Further investigation is required to elucidate whether those genomic imbalances may be considered as molecular risk factors for secondary leukemogenesis.

Materials and methods

ACGH analysis. DNA extraction was performed using a commercial kit (QIAamp DNA kit from Qiagen) according to manufacturer's instructions and quantified by means of NanoDrop Technology (Wilmington). Low DNA amounts were amplified by means of DOP-PCR (Roche). GenoSensor array 300 microarrays (Abbott Vysis Inc.) consisted of 287 probes spotted in triplicate. Briefly, test and reference DNAs, after random priming labelling with Cy3-dCTP and Cy5-dCTP (Amersham Biosciences) and electrophoresis resolution in 1.5% agarose gel to confirm their length range between 100 and 600 bp, were denatured at 80°C for 10 min in 25 μ l hybridization buffer containing human Cot-I DNA and hybridized on microchips at 37°C for 72 h. After washing microarrays were counterstained with DAPI IV (Abbott Vysis Inc.). The images were captured and analyzed with the GenoSensor reader system (Abbott Vysis Inc.). Only those probes with at least 2 available spots were considered for analysis (spot measurements were highly reproducible, thus two spots are considered sufficient) and the average over the spots was taken as the copy number ratio for that gene. Thresholds for gene amplification and deletion were 1.2 and 0.82, respectively (15).

Fluorescence in situ hybridization (FISH). FISH was performed on sections from formalin-fixed, paraffin-embedded biopsy blocks using the following commercially available fluorescence-labelled, locus-specific (LSI) N-myc and CDKN 2A (p16) and associated centromere DNA probes (CEP) (Abbott Vysis Inc.). Fifty nuclei per sample were scored for each LSI probe. Digital images were acquired with a Nikon Eclipse 1000 fluorescence microscope. Amplifications and deletions were detected when the ratio between the number of spots of test gene and of internal reference gene was greater than 2N+1 or lower than 1 respectively, with N corresponding to the number of spots of the internal reference gene.

Immunohistochemistry. Tissue sections (3 μ m) formalin-fixed, paraffin-embedded blocks were coated on electrically charged slides, dewaxed and rehydrated, and then submitted

to antigen retrieval by micro-waving in 1 mM EDTA (pH 8.0) at 900 W (3 cycles of 5 min each). After cooling, slides were incubated for 30 min at room temperature with primary antibodies [PPARBP and GATA3 from Santa Cruz Biotech., Top1, FGFR1 and FGR(SRC2) from Abcam, FES from Abgent, HRAS and WT1 from Dako]. Antibody binding was detected by the alkaline phosphatase anti-alkaline phosphatase technique or by the peroxidase-based LSAB method (Dako) and sections were then counterstained with hematoxylin.

Polymerase chain reaction (PCR). PCR reactions were performed in T Personal instrument by Biometra according to the following cycle profile: denaturation at 98°C for 30 sec, annealing at 59°C for 30 sec and extension 72°C for 1 min. Thirty cycles were carried out for PCR amplification of β -actin. Amplification products (226 bp) were then resolved in 1% agar and signal intensities measured by densitometric analysis. β -actin primers sequences are: 5'CATGTGCAAG GCCGGCTTC 3' (upper) and 3'GAAGGTGTGTGGTGC CAGATTT 5' (lower). PCR reactions were carried out on a total amount of 500 ng of DOP-PCR (Roche kit) products in PCR reaction buffer containing 50 nM Tris pH 8.4, 250 μ g/ml BSA, 3 mM MgCl₂, 2 mM dNTPs, 4 U Taq polymerase and 0.5 μ M specific primers.

Results and Discussion

The cumulative incidence of secondary acute myeloid leukemias (AML) in HL ranges from 0.8% to 6.3%. It is mostly restricted to the first 5-7 years after treatment and correlated with the genotoxic damage induced by chemotherapy protocols including alkylating drugs (mechlorethamine, in particular) (12). In our cohort of 1,224 classic HL patients (corresponding to 0.89%) 11 underwent this therapy-related outcome (data not shown). To investigate whether individual discrete genomic imbalances at diagnosis would distinguish patients prone to AML development during HL follow-up we used an aCGH strategy (GenoSensor array 300 purchased from Abbott Vysis Inc.). In preliminary experiments (data not shown) we did not detect differences in DNA sequence copy numbers of whole lymph node and peripheral blood mono-nuclear cells from 2 normal persons and 2 classic HL patients at diagnosis (with <2% neoplastic component), supporting that aCGH mirror the individual genotypic profiles. However, the putative impact of neoplastic lymph node microenvironment and/or infection (in particular by Epstein-Barr virus) on genomic profiles of diverse lymph node cellular components possibly relevant for HL prognosis requires further investigation in a larger number of patients and using different techniques (aCGH technique only detects amplifications and deletions but does not provide any information on gene expression) (16,17).

Good quality DNA suitable for aCGH analysis was obtained from lymph node biopsies of 3 out of 11 classic HL cases who developed AML (see Table I for clinical details). They were used as tests in a first aCGH series set using pooled DNAs from 8 reactive lymph node biopsies as reference. To confirm the good quality of DNA used in aCGH, PCR reactions for β -actin were performed on DOP-PCR products of all patients involved in the study (3 classic HL and 3

SPANDIDOS Clinical details of classic HL patients included in the PUBLICATIONS

A, Patients who develop AML

	Patient 1	Patient 2	Patient 3
HL			
Histological type	Nodular sclerosis	Unclassified	Nodular sclerosis
Clinical stage at diagnosis	IV B (bone)	III B	II A (bulky mediastinum)
Chemotherapy	8 MOPP cycles+ 8 ABVD cycles	6 VBM cycles+ 3 MOPP cycles	6 ABVD cycles
Radiotherapy	Not done	Lomboaortic lymph nodes, spleen	Not done
Interval between HL diagnosis and AML outcome	58 months	76 months	25 months
AML			
Morphologic subtype ^a	M1	M0-M1	M3
Cytogenetics	Normal karyotype	Normal karyotype	tt(15;17)(q22;q12) del(7)(q22;q32) del(9)(q13;q31)

B, Patients who did not develop AML

	Patient 4	Patient 5	Patient 6
HL			
Histological type	Nodular sclerosis	Nodular sclerosis	Nodular sclerosis
Clinical stage at diagnosis	III A	IV B (lung and spleen)	II A (bulky mediastinum)
Chemotherapy	8 MOPP cycles+ 8 ABVD cycles	6 ABVD cycles+ 8 ABVD cycles	4 ABVD cycles
Radiotherapy	Not done	Sovraclavicular and laterocervical lymph nodes, mediastinum	Sovraclavicular and laterocervical lymph nodes, mediastinum

Patients 1, 2 and 3 developed AML. Patients 4, 5 and 6, who did not develop any secondary malignancy, were comparable to the first group of patients for histological type, clinical stage and follow-up. ^aAccording to FAB classification.

classic HL who developed AML) and of pooled DNAs from normal persons (Fig. 1). Genomic imbalances included 44 amplifications and 28 deletions. Of 44 amplifications, 24 were common to all 3 patients, 17 to 2 patients and the remaining 3 were seen only in 1 patient (Table IIA). Out of 28 deletions, 5 were common to all 3 patients, 12 were shared by 2 patients and the remaining 11 were seen only in 1 patient (Table IIB).




Figure 1. Polymerase chain reaction (PCR) for β -actin. PCR reactions for β -actin were performed in DOP-PCR products of all patients involved in the study. Pooled DNAs from normal persons and the six patients showed comparable levels of β -actin gene, confirming the good quality of DNA used in aCGH.




Figure 2. Results of FISH analysis relative to MYCN (N-Myc) and CDKN 2A (p16). FISH analysis was performed on paraffin-embedded lymph node biopsies of normal persons (the only one shown here is representative of all), 3 HL patients who developed AML (bars 1, 2 and 3) and 3 HL patients (comparable for histological type, clinical stage and follow-up) who did not develop any secondary malignancy (bars 4, 5 and 6). FISH was performed on sections from formalin-fixed, paraffin-embedded biopsies as described in Materials and methods. Cep2 and cep9 centromeric regions were used as references for the signal copy number in single nuclei.

ACGHs results relative to MYCN (N-Myc) amplification and CDKN 2A (p16) deletion were validated by FISH. We analysed ratio between number of spots of test genes [MYCN (N-Myc) and CDKN 2A (p16)] and of internal reference genes (cep2 and cep9 respectively) (Fig. 2). Notably, most genomic imbalances shared by at least 2 classic HL patients who developed AML were also found in aCGH set using DNAs

Table II. Genomic imbalances in classic HL patients who developed secondary AML relative to normal controls.

A, Amplifications				
Genes and regions	Chromosomal locus	1	2	3
16PTEL03	16p tel	1.22	1.42	1.66
20QTEL14	20q tel	1.68	1.39	2.08
6QTEL54	6q tel	1.80	1.32	2.64
7QTEL20	7q tel	1.29	1.43	2.04
8M16/SP6	12p tel	1.50	1.46	2.68
ARHGAP8	22q13.3	1.33	1.26	1.33
ATM	11q22.3	1.24	1.26	2.12
CDC2L1(p58)	1p36	1.21	1.41	2.18
D10S167	10p11-10q11	1.26	1.26	2.03
D13S25	13q14.3	1.24	1.21	1.71
D17S1670	17q23	1.24	1.30	1.59
EGR1	5q31.1	1.57	1.46	1.99
ELN	7q11.23	1.47	1.59	2.46
ERBB2 (HER-2)	17q11.2-17q12	1.59	1.28	1.71
FES	15q26.1	1.30	1.47	1.83
GLI	12q13.2-q13.3	1.32	1.27	1.21
GSCl	22q11.21	1.53	1.23	2.04
HRAS	11p15.5	2.57	1.70	3.09
INS	11p tel	1.30	3.00	2.68
MYCN (N-myc)	2p24.1	1.21	1.34	1.41
PTGS2 (COX2)	1q31.1	1.58	1.28	2.33
RB1	13q14	1.39	1.30	1.61
SNRPN	15q12	1.21	1.53	2.01
SRY	Yp11.3	1.35	1.29	1.86
D21S378	21q11.2	1.35	1.18	1.26
D5S23	5p15.2	1.30	1.32	2.05
D6S434	6q16.3	1.33	1.05	1.84
D2S447	2q tel	1.88	2.54	1.06
ABL1	9q34.1	1.33	1.02	1.42
D3S1274, ROBO1	3p12-3p13	1.33	0.90	1.61
DCC	18q21.3	1.83	1.10	2.84
BRCA2	13q12-q13	1.23	0.95	1.24
CDK6	7q21-22	1.30	0.71	1.54
E2F5	8p22-q21.3	2.09	1.17	2.47
PIM1	6p21.2	1.62	1.09	1.85
CSF1R	5q33-35	1.08	1.31	1.25
SGC34236	2q13	1.11	1.44	2.09
WHSC1	4p16.3	1.10	1.23	1.54
PDGFB (SIS)	22q13.1	0.56	1.63	2.02
OCRL1	Xq25	0.85	1.24	1.30
KAL	Xp22.3	1.19	1.21	1.96
IGH (SHGC-36156)	14q tel	1.14	0.82	1.35
D6S268	6q16.3-q21	1.18	1.00	1.47
D13S319	13q14.2	1.08	1.10	2.09

Table II. Continued.

B, Deletions				
Genes and regions	Chromosomal locus	1	2	3
EGR2	10q21.3	0.80	0.62	0.68
ESR1	6q25.1	0.73	0.81	0.66
EST CDY16	X/Yq tel	0.77	0.77	0.62
MLL	11q23	0.82	0.80	0.81
PIK3CA	3q26.3	0.81	0.69	0.67
MAP2K5	15q23	0.67	0.93	0.66
RAF1	3p25	0.81	1.02	0.75
MYB	6q22-q23	0.83	0.58	0.68
ABCB1 (MDR1)	7q21.1	1.00	0.55	0.72
CDKN 2A (p16)	9p21	0.85	0.76	0.66
CYP 24	20q13.2	0.91	0.66	0.73
D1S2465	1p12	0.92	0.65	0.61
ITGA4	2q31-q32	0.91	0.62	0.76
SHGC-182	1q tel	1.17	0.57	0.69
TGFB2	1q41	0.90	0.79	0.73
stSG42796	19p tel	1.13	0.57	0.73
TERC	3q26	1.05	0.65	0.75
RASSF1	3p21.3	0.78	1.49	0.96
IGH	14q tel-2	1.14	0.82	1.35
DAB2	5p13	0.98	0.67	0.91
KAI1	11p11.2	0.94	0.83	0.67
BCL2 3'	18q21.3	0.92	0.83	0.65
D19S238E	19q tel	1.00	0.93	0.77
LPL	8p22	0.94	0.89	0.65
TCL1A	14q32.1	0.88	0.99	0.81
ABCC1 (MRP1)	16p13.1	0.88	0.95	0.72
D6S311	6p23-24	0.94	0.87	0.81
TK1	17q23.2-q25.3	0.98	0.90	0.75

ACGHs were performed using DNA from whole formalin-fixed, paraffin-embedded lymph node biopsies of individual classic HL patients who developed secondary AML at diagnosis as test and pooled DNAs from 8 reactive lymph nodes as reference. Panels A and B show in sequence amplifications and deletions seen in 3, 2 or only 1 HL patient. Bold characters distinguish genes and regions shared by at least 2 out of 3 classic HL patients comparable for histological type, clinical stage and follow-up who did not develop any secondary malignancy (see Table IIIA and B).

from 3 classic HL patients who did not develop any secondary cancer (comparable for histological type, clinical stage and follow-up) as tests and pooled DNAs from 8 reactive lymph node biopsies as reference (Table IIIA and B). They encompass genes involved in genomic stability and concerning, in particular, telomeric regions (16PTEL03, 20QTEL14, 6QTEL54, 8M16/SP6, INS, EST CDY16, stSG42796), growth factor and hormone receptors (EGR1, ERBB2, FES, EGR2, ESR1), regulators of cell cycle progression (RB1, CDKN2A), apoptosis [PTGS2 (COX2)] and chromatin epigenetic structure (MLL), and signal transduction signals (HRAS, MYCN, MYB, PIK3CA, MAPK2K5). In conclusion, our results suggest a

A, Amplifications

Genes and regions	4	5	6
16PTL03	1.14	1.35	1.01
20QTEL14	1.12	3.08	1.87
6QTEL54	1.09	3.55	1.87
7QTEL20	1.04	1.70	1.03
8M16/SP6	1.11	3.46	1.97
ARHGAP8	0.95	1.21	0.96
ATM	1.16	2.81	1.06
CDC2L1 (p58)	1.11	1.62	1.15
D10S167	1.09	1.73	1.24
D13S25	1.45	1.61	2.77
D17S1670	0.92	2.20	1.36
EGR1	1.69	2.64	1.23
ELN	1.49	2.51	1.26
ERBB2 (HER-2)	1.08	2.29	1.54
FES	1.64	1.78	2.32
GLI	1.13	1.40	1.24
GSC	1.08	2.56	1.45
HRAS	1.35	4.43	2.75
INS	1.34	3.87	2.35
MYCN (N-myc)	1.29	1.50	1.75
PTGS2 (COX2)	1.03	2.61	1.82
RB1	1.00	2.15	1.61
SNRPN	1.20	2.20	1.43
SRY	1.07	1.95	1.33
D21S378	1.41	1.73	2.59
D5S23	1.07	3.14	1.40
D6S434	1.29	2.22	2.23
D2S447	4.08	0.96	2.74
ABL1	0.98	1.75	1.03
D3S1274, ROBO1	1.01	2.54	1.31
DCC	-	4.45	1.63
BRCA2	0.84	1.51	0.92
CDK6	0.92	1.86	1.29
E2F5	1.09	4.08	2.29
PIM1	1.17	2.95	1.66
CSF1R	1.38	1.54	1.77
SGC34236	1.21	2.43	1.31
WHSC1	1.25	1.53	2.17
PDGFB (SIS)	1.24	1.56	1.13
OCRL1	1.16	0.95	1.36
KAL	0.89	2.46	1.50
IGH (SHGC-36156)	0.84	1.93	1.23
D6S268	1.10	1.79	1.28
D13S319	0.90	2.42	1.28
AFM217YD10	1.36	1.66	1.88
FGR(SRC2)	1.44	1.29	2.20
GATA3	1.09	1.88	1.36
TOP1	1.61	1.98	2.51
WT1	1.80	1.91	2.52
DRIM, ARL1	1.21	1.28	1.31
TBR1	1.35	1.24	1.58

Table III. Continued.

B, Deletions

Genes and regions	4	5	6
EGR2	0.78	0.66	0.57
ESR1	0.78	0.72	0.64
EST CDY16	0.69	0.70	0.53
MLL	0.79	0.78	0.41
PIK3CA	0.66	0.94	0.38
MAP2K5	0.76	0.68	0.55
RAF1	1.07	0.78	0.86
MYB	0.84	0.67	0.53
ABCB1 (MDR1)	0.82	0.63	0.46
CDKN 2A (p16)	0.71	0.67	0.55
CYP 24	0.80	0.66	0.46
D1S2465	0.72	0.61	0.53
ITGA4	0.81	0.74	0.73
SHGC-182	0.68	0.60	0.42
TGFB2	0.81	0.75	0.63
stSG42796	0.83	0.90	0.76
TERC	0.99	0.72	0.65
RASSF1	1.21	0.50	0.94
IGH	0.86	0.63	0.56
DAB2	0.87	0.85	0.62
KAI1	0.90	0.79	0.49
BCL2 3'	0.79	0.62	0.47
D19S238E	1.01	0.69	0.79
LPL	0.77	0.68	0.64
TCL1A	0.97	0.70	0.83
ABCC1 (MRP1)	1.12	0.70	0.96
D6S311	1.08	0.78	1.02
TK1	0.91	0.85	0.59

ACGH were performed using DNA from whole formalin-fixed, paraffin-embedded lymph node biopsies of individual classic HL patients at diagnosis (comparable to those who developed AML for histological type, clinical stage and follow-up) as test and pooled DNAs from 8 reactive lymph nodes as reference. Bold characters distinguish genes and regions shared by at least 2 out of 3 of them.

wide individual variability in the DNA sequence copy number associated with classic HL likely independent from further evolution of the disease.

To distinguish genomic imbalances eventually associated with the development of secondary AML we set aCGH using individual DNAs from lymph node biopsies of classic HL patients who developed AML as tests and pooled DNAs from lymph nodes of 3 HL patients (comparable for histological type, clinical stage and follow-up) who did not develop any secondary malignancy as reference. ACGH results underscored a high degree of variability in genomic imbalances associated with AML development concerning all genes and regions whose copy number relative to normal controls was altered (Table VI). The number of amplifications and deletions in patient 3 (the only one exhibiting complex karyotypic abnormalities in leukemic progenitors) largely exceeded that

Table VI. Genomic imbalances in classic HL patients who developed AML relative to HL patients who did not develop any secondary malignancy.

A, Amplifications			
Genes and regions	1	2	3
6QTEL54	0.81	0.88	1.41
7QTEL20	0.91	1.23	1.38
8M16/SP6	0.79	0.89	1.28
ATM	0.96	0.93	1.59
CDC2L1 (p58)	0.75	0.91	1.31
D10S167	0.87	1.02	1.34
D17S1670	0.81	0.99	1.21
EGR1	0.80	0.87	1.25
ELN	0.74	0.97	1.39
ERBB2 (HER-2)	0.86	1.07	1.35
GSCL	1.01	1.04	1.44
HRAS	4.73	1.01	1.08
INS	0.85	1.28	1.35
PTGS2 (COX2)	1.05	0.96	1.72
RB1	0.93	0.95	1.47
SNRPN	0.92	0.93	1.78
SRY	0.79	0.83	1.22
D21S378	0.87	0.68	1.21
D5S23	1.08	0.99	1.64
D3S1274, ROBO1	1.00	0.87	1.53
CDK6	1.01	0.99	1.51
E2F5	0.79	0.92	1.32
PIM1	0.89	0.94	1.36
SGC34236	0.81	0.96	1.37
IGH (SHGC-36156)	1.04	0.92	1.21
D6S268	0.88	0.89	1.24
D13S319	0.86	0.99	1.57

B, Deletions

Genes and regions	1	2	3
EGR2	1.28	0.79	0.61
ESR1	1.08	0.76	0.58
EST CDY16	1.31	0.81	0.69
MAP2K5	1.18	0.96	0.60
CDKN 2A (p16)	1.26	0.80	0.84
CYP 24	1.32	0.94	0.81
D1S2465	1.14	0.86	0.50
TGFB2	1.05	0.96	0.70
BCL2 3'	1.11	1.12	0.81
LPL	1.03	1.06	0.81
ABCC1 (MRP1)	0.99	1.18	0.73
D6S311	0.89	0.88	0.78

ACGHs were performed using DNA from formalin-fixed, paraffin-embedded lymph node biopsies of individual HL patients who developed AML as test and pooled DNAs from lymph node biopsies of HL patients who did not develop any secondary malignancy (comparable for clinical feature, histological type and follow-up) as reference. Bold characters distinguish genomic imbalances in individual patients. In all cases those genomic imbalances concern genes and regions whose copy number relative to normal controls was found altered (see Table IIA and B).

Table V. Genomic imbalances shared by all 3 HL patients who developed AML relative to HL patients who did not develop any secondary malignancy.

A, Amplifications				
Genes and regions	Chromosomal locus	1	2	3
AFM137XA11	9p11.2	1.67	1.24	1.59
FGFR1	8p11.2-p11.1	1.22	1.29	1.30
PPARBP	17q12	1.37	1.38	1.21
B, Deletions				
Genes and regions	Chromosomal locus	1	2	3
AFM217YD10	17q tel	0.65	0.72	0.66
FGR(SRC2)	1p36.2-p36.1	0.56	0.81	0.66
GATA3	10p15	0.75	0.79	0.61
TOP1	20q12-q13.1	0.64	0.65	0.72
WT1	11p13	0.59	0.69	0.68

See legends to Table IV for details on aCGH.

seen in patients 1 and 2 (Table I). Genomic imbalances shared by all 3 patients included 3 amplifications, encompassing genes and regions whose copy numbers relative to normal controls were not altered, and 5 deletions, due to the loss of amplification seen in classic HL patients who did not develop secondary leukemia) (Table VA and B).

To confirm aCGH results and distinguish the distribution of either amplified or deleted gene product in different lymph node components we performed immunohistochemistry analysis. The results of immunohistochemistry analyses in lymph node biopsies of patients #2 and #6 shown in Fig. 3 are representative of all. A significant reduction of the expression of FGR(SRC2) and TOP1 proteins, apparent in lymph node biopsies from HL patients who developed secondary AML compared to those who did not develop any secondary malignant neoplasia, concerned both the neoplastic (RS cells) and non-neoplastic lymph node components (Fig. 3). Conversely, the expression of WT1 protein was lacking in RS cells of either patient group and significantly reduced in non-neoplastic components of lymph node biopsies of HL patients who developed secondary AML. Furthermore, FGFR1 overexpression in lymph node biopsies of HL patients who developed AML concerned the non-neoplastic lymph node components. Results relative to PPARBP amplification and GATA3 deletion were impaired by the inadequate antibody specificity.

In conclusion, the number of patients included in our study is too limited to assert that genomic imbalances that we found earn consideration as molecular risk factors for secondary AML in HL. Our results must be confirmed in a larger cohort of HL patients. Moreover, the role of individual genomic imbalances in secondary leukemogenesis process requires further investigation. Previous studies proved that




Figure 3. Immunohistochemistry of lymph node biopsies from normal persons and classic HL patients. The panels show in sequence FGR(SRC2), TOP1, WT1 and FGFR1 expression in lymph node biopsies from a normal control (reactive lymph node biopsy), one classic HL patient who developed AML (#2) and one classic HL patient who did not develop any secondary malignancy (#6). The expression of above mentioned proteins in RS cells are represented in detail in the inserts at the top of the single panels. Results were confirmed in lymph node biopsies of other normal controls and HL patients. Immunohistochemistry analyses were performed on formalin-fixed, paraffin-embedded tissue sections according to the method described in detail in Materials and methods.

WT1 and FGR(SRC2) participate in the immune response against leukemic clones and that TOP1 and FGFR1 intervene in DNA repair (18,19). In particular, TOP1 deletion impairs p53-dependent recombination repair by precluding DNA cleavage in the vicinity of lesions and FGFR1 overexpression targets the centrosome where it activates signalling pathways via tyrosine phosphorylation and allows continuous cell cycle progression (20,21). They might, therefore, concurrently promote the selection of genetic aberrations in an early myeloid compartment leading to the emergence of leukemic progenitors whose recognition and lysis by CD4⁺ T and NKT cells is precluded by WT1 and FGR(SRC2) loss.

Acknowledgements

The study was supported by the University of Bologna (ex60% funds and Progetti Pluriennali), Carisbo Foundation and BolognaAIL. G.B. is a Postdoctoral fellow of Dipartimento di Scienze Radiologiche e Istocitopatologiche, University of Bologna-Medical School. M.M. is the recipient of a Postdoctoral grant of the University of Bologna-Medical

School. P.C. is the recipient of a grant from Centro Interdipartimentale di Ricerca sul Cancro 'Giorgio Prodi' of the University of Bologna.

References

1. Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, Begg CB, Caporaso N, Chanock S, DeMichele A, Figg WD, Gospodarowicz MK, Hall EJ, Hisada M, Inskip P, Kleinerman R, Little JB, Malkin D, Ng AK, Offit K, Pui CH, Robison LL, Rothman N, Shields PG, Strong L, Taniguchi T, Tucker MA and Greene MH: Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations: Review. *J Natl Cancer Inst* 98: 15-25, 2006.
2. Brauner A, Schmitz R, Bechtel D, Renne C, Hansmann ML and Kuppers R: Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. *Int J Cancer* 118: 1853-1861, 2006.
3. Re D, Zander T, Dieh V and Wolf J: Genetic instability in Hodgkin's lymphoma. *Ann Oncol* 13 (Suppl 1): 19-22, 2002.
4. Barrios L, Caballin MR, Miro R, Fuster C, Berrozpe G, Subias A, Batlle X and Egozcue J: Chromosome abnormalities in peripheral blood lymphocytes from untreated Hodgkin's patients. A possible evidence for chromosome instability. *Hum Genet* 78: 320-324, 1988.

5. Erdkamp FL, Schouten HC, Breed WP, Janssen WC, Hoffmann JJ, Schutte B and Blijham GH: DNA aneuploidy in Hodgkin's disease: a multiparameter flow cytometric analysis. *Leuk Lymphoma* 12: 297-306, 1994.
6. Schlegelberger B, Weber-Matthiesen K, Sterry W, Bartels H, Sonnen R, Maschmeyer G, Feller AC and Grote W: Combined immunophenotyping and karyotyping in peripheral T cell lymphomas demonstrating different clonal and nonclonal chromosome aberrations in T helper cells. *Leuk Lymphoma* 15: 113-125, 1994.
7. Jansen MP, Hopman AH, Haesevoets AM, Gennotte IA, Bot FJ, Arends JW, Ramaekers FC and Schouten HC: Chromosomal abnormalities in Hodgkin's disease are not restricted to Hodgkin/Reed-Sternberg cells. *J Pathol* 185: 145-152, 1998.
8. Re D, Starostik P, Massoudi N, Staratschek-Jox A, Dries V, Thomas RK, Diehl V and Wolf J: Allelic losses on chromosome 6q25 in Hodgkin and Reed Sternberg cells. *Cancer Res* 63: 2606-2609, 2003.
9. Wang SS, Davis S, Cerhan JR, Hartge P, Severson RK, Cozen W, Lan Q, Welch R, Chanock SJ and Rothman N: Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. *Carcinogenesis* 27: 1828-1834, 2006.
10. Shen M, Zheng T, Lan Q, Zhang Y, Zahm SH, Wang SS, Holford TR, Leaderer B, Yeager M, Welch R, Kang D, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S and Rothman N: Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. *Hum Genet* 119: 659-668, 2006.
11. Re D, Benenson L, Wickenhauser C, Starostik P, Staratschek-Jox A, Muller-Hermelink HK, Diehl V and Wolf J: Proficient mismatch repair protein expression in Hodgkin and Reed Sternberg cells. *Int J Cancer* 97: 205-210, 2002.
12. Pedersen-Bjergaard J: Insights into leukemogenesis from therapy-related leukemia. *N Engl J Med* 352: 1591-1594, 2005.
13. Kelly KM and Perentesis JP: Polymorphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin's lymphoma at risk of treatment-related complications. *Ann Oncol* 13 (Suppl 1): 34-39, 2002.
14. Jawad M, Seedhouse CH, Russell N and Plumb M: Polymorphisms in human homeobox HLX1 and DNA repair RAD51 genes increase the risk of therapy-related acute myeloid leukaemia. *Blood* 108: 3916-3918, 2006.
15. Hattinger CM, Tarkkanen M, Benini S, Pasello M, Stoico G, Bacchini P, Knuutila S, Scotlandi K, Picci P and Serra M: Genetic analysis of fibrosarcoma of bone, a rare tumour entity closely related to osteosarcoma and malignant fibrous histiocytoma of bone. *Eur J Cell Biol* 83: 483-491, 2004.
16. Liu MT, Chang YT, Chen SC, Chuang YC, Chen YR, Lin CS and Chen JY: Epstein-Barr virus latent membrane protein 1 represses p53-mediated DNA repair and transcriptional activity. *Oncogene* 24: 2635-2646, 2005.
17. Sanchez-Aguilera A, Montalban C, de la Cueva P, Sanchez-Verde L, Morente MM, Garcia-Cosio M, Garcia-Larana J, Bellas C, Provencio M, Romagosa V, de Sevilla AF, Menarquez J, Sabin P, Mestre MJ, Mendez M, Fresno MF, Nicolas C, Piris MA, Garcia JF and Spanish Hodgkin Lymphoma Study Group: Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. *Blood* 108: 662-668, 2006.
18. Guo Y, Niiya H, Azuma T, Uchida N, Yakushijin Y, Sakay I, Hato T, Takahashi M, Senju S, Nishimura Y and Yasukawa M: Direct recognition and lysis of leukemia cells by WT1-specific CD4⁺ T lymphocytes in an HLA class II-restricted manner. *Blood* 106: 1415-1418, 2005.
19. Sasanuma H, Tatsuno A, Hidano S, Ohshima K, Matsuzaki Y, Hayashi K, Lowell CA, Kitamura D and Goitsuka R: Dual function for the adaptor MIST in IFN-gamma production by NK and CD4+NKT cells regulated by the Src kinase Fgr. *Blood* 107: 3647-3655, 2006.
20. Gurevich P, Aplan DA and Humphries RK: NUP98-Topoisomerase I acute myeloid leukemia-associated fusion gene has potent leukemogenic activities independent of an engineered catalytic site mutation. *Blood* 104: 1127-1136, 2004.
21. Karajannis MA, Vincent L, Drenzo R, Shmelkov SV, Zhang F, Feldman EJ, Zhu Z, Sun H, Kussie P and Rafii S: Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells. *Leukemia* 20: 979-986, 2006.